Notifications

Home

Stocks
- Stock Screener
- Market Movers
- Insider Trades
- Upcoming Earnings
- Upcoming Dividends
Options
- Unusual Options Activity
- Implied Volatility Rank
- Volatility %Change
News
Upcoming IPOs

Chemomab Therapeutics Ltd ADR (CMMB)

$2.27 +0.57 (33.53%)

Overview
Financial
Short Interest
Institutional Holdings
Dividends
Charts

Market Cap	16.35M
Revenue (ttm)	0.00
Net Income (ttm)	-9.00M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,393,400
Avg Vol	72,204
Day's Range	N/A - N/A
Shares Out	7.20M
Stochastic %K	84%
Beta	0.64
Analysts	Strong Sell
Price Target	$15.00

Company Profile

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemi...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 77 331 0156

Website: www.chemomab.com

Address:

Building C, 10th Floor 10 Habarzel Street, Tel Aviv-Yafo, Israel

StockScanners Jul. 4 at 4:58 PM

$CMMB keep watch if this holds above 2.26

0 · Reply

dom3 Jul. 3 at 1:20 PM

$CMMB Remember; we are still waiting for the first back to back day of higher than normal volume. Every other time it has failed...early trading will be the indicator

0 · Reply

BananaBrawler Jul. 3 at 11:49 AM

$CMMB

0 · Reply

topstockalerts Jul. 3 at 3:24 AM

Top Gainers PT2 $SLBT $HLP $USDE.X $CMMB $SDEV

0 · Reply

topstockalerts Jul. 2 at 9:39 PM

Top Gainers PT2 $SLBT $HLP $CMMB $SDEV $USDE

0 · Reply

ALRAE Jul. 2 at 9:04 PM

$CMMB

0 · Reply

Mm6899 Jul. 2 at 8:58 PM

$CMMB leaked 🫢

0 · Reply

topstockalerts Jul. 2 at 8:44 PM

$CMMB I underestimated how much demand was here.

0 · Reply

DLTT4489 Jul. 2 at 8:32 PM

$CMMB dump will come soon 😜

0 · Reply

Newmoves Jul. 2 at 8:02 PM

$CMMB what is realistic expectations to how much share price can go to with good news?

1 · Reply

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

May 14, 2026, 8:00 AM EDT - 7 weeks ago

Chemomab Therapeutics Earnings release: Q1 2026

2026-03-19T12:11:46.000Z - 3 months ago

Chemomab Therapeutics sees cash runway through 1Q27

2026-03-19T12:05:34.000Z - 3 months ago

Chemomab Therapeutics reports FY25 EPS (1c) vs. (4c) last year

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Chemomab Therapeutics Annual report: Q4 2025

Mar 19, 2026, 8:00 AM EDT - 3 months ago

Chemomab Therapeutics Earnings release: Q4 2025

Mar 1, 2026, 6:00 AM EST - 4 months ago

Chemomab Therapeutics Slides: Corporate presentation

Feb 26, 2026, 8:00 AM EST - 4 months ago

Chemomab Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 17, 2026, 8:00 AM EST - 4 months ago

Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

2025-12-02T13:15:59.000Z - 7 months ago

Chemomab Therapeutics announces results of its Phase 2 SPRING trial

Dec 2, 2025, 8:00 AM EST - 7 months ago

Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

Nov 24, 2025, 8:00 AM EST - 7 months ago

Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit

Nov 21, 2025, 7:00 AM EST - 8 months ago

Chemomab Therapeutics Earnings release: Q3 2025

2025-11-20T13:05:27.000Z - 8 months ago

Chemomab Therapeutics reports Q3 EPS (0.4c) vs (1c) last year

Nov 20, 2025, 8:00 AM EST - 8 months ago

Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update

2025-11-06T13:47:57.000Z - 8 months ago

Chemomab announces presentations at AASLD 2025 on nebokitug data

Nov 6, 2025, 8:00 AM EST - 8 months ago

Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

2025-09-12T16:55:11.000Z - 10 months ago

Chemomab Therapeutics management to meet with Maxim

Sep 5, 2025, 7:00 AM EDT - 10 months ago

Chemomab Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

2025-08-27T16:21:06.000Z - 11 months ago

Chemomab Therapeutics price target raised to $25 from $10 at Oppenheimer

2025-08-25T23:50:06.000Z - 11 months ago

Chemomab Therapeutics Ltd – ADR trading halted, news pending

Aug 21, 2025, 8:00 AM EDT - 11 months ago

Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

2025-08-14T12:11:23.000Z - 11 months ago

Chemomab Therapeutics reports Q2 EPS 0.4c vs 0.013c last year

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 13, 2025, 6:00 PM EDT - 11 months ago

Chemomab Therapeutics Earnings release: Q2 2025

2025-07-31T17:55:26.000Z - 1 year ago

Chemomab Therapeutics management to meet with Maxim

2025-06-30T14:35:01.000Z - 1 year ago

Chemomab Therapeutics announces data from Phase 2 SPRING trial of nebokitug

Jun 30, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live'25

2025-06-11T12:05:42.000Z - 1 year ago

Chemomab obtained feedback from two recent FDA meetings on nebokitug

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

2025-06-03T12:05:13.000Z - 1 year ago

Chemomab announces nebokitug awarded new patent protection in China, Russia

Jun 3, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

2025-05-16T11:36:15.000Z - 1 year ago

Chemomab Therapeutics price target lowered to $10 from $11 at Oppenheimer

2025-05-15T12:16:43.000Z - 1 year ago

Chemomab Therapeutics reports Q1 EPS $0.007 vs $0.014 last year

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics Earnings release: Q1 2025

2025-05-05T12:11:50.000Z - 1 year ago

Chemomab Therapeutics announces presentation of Phase 2 data of CM-101

May 5, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis in Distinguished Plenary Session at DDW 2025

2025-04-28T12:31:07.000Z - 1 year ago

Chemomab Therapeutics reports new clinical data at EASL 2025 on nebokitug

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases

Apr 21, 2025, 8:00 AM EDT - 1 year ago

Chemomab Therapeutics to Present Nebokitug Clinical Data at Upcoming Scientific Conferences

2025-04-15T12:23:08.000Z - 1 year ago

Chemomab Therapeutics appoints Weiner as interim CMO, Lawler as CDO

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Chemomab Announces New Medical and Clinical Appointments

Mar 27, 2025, 8:30 AM EDT - 1 year ago

Chemomab Reports Positive Results in Nebokitug Phase 2 PSC Open Label Extension Trial Showing Continued Broad and Substantial Improvements in Key Liver Biomarkers

Mar 6, 2025, 8:00 AM EST - 1 year ago

New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Mar 3, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2024 Financial Results and Provides a Corporate Update

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Annual report: Q4 2024

Mar 3, 2025, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q4 2024

Feb 19, 2025, 7:00 AM EST - 1 year ago

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Feb 11, 2025, 8:00 AM EST - 1 year ago

Chemomab Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference 2025

Nov 19, 2024, 7:00 AM EST - 1 year ago

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab's CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Nov 14, 2024, 7:00 AM EST - 1 year ago

Chemomab Therapeutics Earnings release: Q3 2024

Aug 23, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Registration statement: Registration Filing

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 21, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q2 2024

Aug 12, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update

Jul 30, 2024, 9:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Closing of $10 Million Private Placement

Jul 26, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Press release: Study Result

Jul 25, 2024, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Slides: Study Result

Jul 25, 2024, 7:38 AM EDT - 2 years ago

Chemomab Therapeutics Announces $10 Million Private Placement

Jul 25, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with Primary Sclerosing Cholangitis

Jun 6, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Presents Data Supporting the Clinical Potential of CM-101 as a Novel Treatment for Primary Sclerosing Cholangitis at EASL 2024 and a Gordon Research Conference

May 17, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Scientific Conferences

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Earnings release: Q1 2024

May 8, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

May 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Present at 2024 Aegis Virtual Conference

Apr 24, 2024, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update

Apr 18, 2024, 7:00 AM EDT - 2 years ago

Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis

Apr 10, 2024, 10:00 AM EDT - 2 years ago

Chemomab Therapeutics Transcript: KOL Event

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024

Mar 25, 2024, 7:06 AM EDT - 2 years ago

Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Annual report: Q4 2023

Mar 7, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q4 2023

Mar 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference

Feb 20, 2024, 7:00 AM EST - 2 years ago

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Feb 14, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Feb 5, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics to Participate in Upcoming Investor Conferences

Jan 30, 2024, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis

Jan 3, 2024, 7:00 AM EST - 2 years ago

Chemomab Announces Completion of Patient Enrollment in CM-101 Phase 2 Primary Sclerosing Cholangitis Trial and Moves Up Expected Topline Readout to Midyear 2024

Nov 16, 2023, 7:00 AM EST - 2 years ago

Chemomab Presentation at ACR Convergence 2023 Provides Further Support for Key Role of Its CCL24 Target in the Pathogenesis of Systemic Sclerosis

Nov 15, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Receives FDA Fast Track Designation for CM-101 for the Treatment of Primary Sclerosing Cholangitis

Nov 13, 2023, 8:00 AM EST - 2 years ago

Chemomab Presents New Clinical Data Supporting CM-101's Anti-Fibrotic/Anti-Inflammatory Activity in Patients with Liver Fibrosis and New Data Highlighting Unique Association of Its CCL24 Target with Key PSC Pathways at AASLD's The Liver Meeting® 2023

Nov 9, 2023, 8:00 AM EST - 2 years ago

Chemomab Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 7:00 AM EST - 2 years ago

Chemomab Therapeutics Earnings release: Q3 2023

Nov 6, 2023, 4:15 PM EST - 2 years ago

Chemomab Therapeutics Discloses Receipt of Nasdaq Notice Regarding Minimum Bid Price Requirement

Oct 30, 2023, 8:00 AM EDT - 2 years ago

Chemomab Therapeutics Registration statement: Registration Filing

Oct 30, 2023, 7:00 AM EDT - 2 years ago

Chemomab Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update

StockScanners Jul. 4 at 4:58 PM

$CMMB keep watch if this holds above 2.26

0 · Reply

dom3 Jul. 3 at 1:20 PM

$CMMB Remember; we are still waiting for the first back to back day of higher than normal volume. Every other time it has failed...early trading will be the indicator

0 · Reply

BananaBrawler Jul. 3 at 11:49 AM

$CMMB

0 · Reply

topstockalerts Jul. 3 at 3:24 AM

Top Gainers PT2 $SLBT $HLP $USDE.X $CMMB $SDEV

0 · Reply

topstockalerts Jul. 2 at 9:39 PM

Top Gainers PT2 $SLBT $HLP $CMMB $SDEV $USDE

0 · Reply

ALRAE Jul. 2 at 9:04 PM

$CMMB

0 · Reply

Mm6899 Jul. 2 at 8:58 PM

$CMMB leaked 🫢

0 · Reply

topstockalerts Jul. 2 at 8:44 PM

$CMMB I underestimated how much demand was here.

0 · Reply

DLTT4489 Jul. 2 at 8:32 PM

$CMMB dump will come soon 😜

0 · Reply

Newmoves Jul. 2 at 8:02 PM

$CMMB what is realistic expectations to how much share price can go to with good news?

1 · Reply

Rolex53 Jul. 2 at 7:41 PM

$CMMB is it up just because of sector? Or any significant news leaked?

1 · Reply

Psuedo_Doji Jul. 2 at 7:33 PM

$CMMB in Gwen we trust

0 · Reply

topstockalerts Jul. 2 at 7:26 PM

Top Gainers PT2 $CMMB $SURG $HLP $WBX $LIMN

0 · Reply

RedDogSailor Jul. 2 at 6:31 PM

$CMMB Any clues why this is up?

1 · Reply

topstockalerts Jul. 2 at 6:25 PM

Top Gainers PT2 $CMMB $SURG $HLP $WBX $LIMN

0 · Reply

SDBiotechInvestor Jul. 2 at 6:07 PM

$CMMB - She was the missing link needed to close a deal. Stock sure is acting like it.

0 · Reply

PriceActionSocietytrades Jul. 2 at 6:03 PM

$MSS is way over sold keep an eye on this one it could break out soon!! $SURG $CLRO $CMMB $USDE

0 · Reply

Newmoves Jul. 2 at 5:37 PM

$CMMB what is going on here news soon or just another random pump?

2 · Reply

30PERCENT40 Jul. 2 at 5:20 PM

$CMMB Nice 🤑 🤑 🤑 🤑

0 · Reply

Snptrader Jul. 2 at 5:11 PM

$CMMB next stop $2.60

0 · Reply

RomeOdessy Jul. 2 at 4:56 PM

Told you BGML is going to be next, they are squeezing it now! Will they send BMGL for 500% next?? could go bigger than $HLP $SURG $LIMN $CMMB imo..

1 · Reply

prismmarketview Jul. 2 at 4:11 PM

PRISM Mid-Day Movers: Weight Loss and Biotech are Today’s Leaders. Allurion Technologies Inc. (OTC: $ALUR) is ripping higher again today, with the stock up about 36%to 4.00 from a prior close of 2.94. Chemomab Therapeutics Ltd. (NASDAQ: $CMMB ) is having a strong session, with the stock up about 32% to 2.2401 from a prior close of 1.70. Other Notable Movers: DarioHealth Corp. ($DRIO ) up 13% LifeMD inc. ( $LFMD ) up 10% Aspira Women’s Health ( $AWH) down -15% https://prismmarketview.com/prism-mid-day-movers-weight-loss-and-biotech-are-todays-leaders-2/

0 · Reply

1.0.0